MOTS-C Information & Coordination for Licensed U.S. Clinics
MOTS-C is the common name used for a 16-amino-acid peptide associated with mitochondrial biology. FDA describes MOTS-c as being encoded by a short open reading frame within mitochondrial 12S rRNA.
FDA evaluated MOTS-c free base and MOTS-c acetate in 2026 as part of its section 503A bulk-drug-substance review. Neither substance is a component of an FDA-approved drug.
Phoenix Meds Inc. supports licensed healthcare organizations with credential review, documentation, publicly available regulatory information, and administrative coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About MOTS-C
The name “MOTS-C” should not be treated as though it identifies a single standardized, FDA-approved medication.
FDA treats MOTS-c free base and MOTS-c acetate as different bulk drug substances. The agency has also noted inconsistent naming conventions involving MOTS-c-related substances and considers that inconsistency relevant to product identity and safety.
FDA’s 2026 review did not identify clinical studies evaluating administration of MOTS-c-related substances in humans. The agency also found no human-exposure data for MOTS-c administered by any route.
For that reason, Phoenix does not promote MOTS-C for weight loss, insulin resistance, metabolic health, longevity, physical performance, osteoporosis, or other treatment outcomes.
Current FDA and Compounding Status
MOTS-c-related bulk drug substances were nominated for consideration under section 503A. The nomination was later withdrawn, but FDA chose to continue evaluating MOTS-c free base and MOTS-c acetate on its own initiative.
FDA states that neither substance has an applicable USP or National Formulary drug-substance monograph and neither is a component of an FDA-approved drug.
After reviewing the available information, FDA concluded that the evaluation criteria weighed against adding either substance to the 503A Bulks List. In July 2026, FDA proposed that MOTS-c free base and MOTS-c acetate not be included on that list.
The advisory-committee process is not, by itself, a final agency rule. Clinics should therefore check current FDA information before relying on a particular compounding pathway.
A pharmacy’s 503A status or an outsourcing facility’s 503B registration also does not automatically establish that a particular bulk substance may be used in compounding. Federal law places separate conditions on the bulk substances that may be used under each framework.
Why Product Identity Matters
FDA’s review found uncertainty around the identity and characterization of MOTS-c-related bulk substances.
The agency notes that MOTS-c is a common name rather than a United States Adopted Name and that different salts or derivatives may be described using similar terminology. FDA considers inconsistent naming a potential safety concern because the material supplied may not be the substance that was intended.
For clinics, that makes documentation important. A product name alone should not be treated as proof of identity, regulatory status, or clinical suitability.
Phoenix can help organize available records and publicly available regulatory information so a clinic can identify questions that need further review.
How Phoenix Meds Supports Licensed Clinics
Our role is administrative.
We may help licensed healthcare organizations review professional credentials, organize supporting documentation, check publicly available licensing and regulatory records, and identify information that needs clarification.
Where documentation is incomplete or inconsistent, we can help organize those questions for review by the appropriate licensed, regulatory, or legal professional.
The purpose is to make the administrative review easier to follow without taking over clinical, pharmaceutical, or legal decisions that belong to other parties.
Phoenix’s review is not FDA approval, pharmacy accreditation, a treatment recommendation, or a legal opinion.
Safety and Documentation Considerations
FDA says it has not identified clinical studies or human-exposure data involving MOTS-c administered by any route.
The agency also identifies potential concerns involving immunogenicity, peptide-related impurities, aggregation, and characterization of the active pharmaceutical ingredient. FDA states that important information needed to determine whether MOTS-c could cause harm in humans is lacking.
FDA additionally found insufficient evidence to evaluate effectiveness for the proposed uses it reviewed and noted that the available literature was limited largely to nonclinical studies.
Phoenix does not manufacture, test, compound, dispense, ship, or take custody of MOTS-C. We also do not certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
MOTS-C Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds Inc. regarding credential review, documentation, and publicly available regulatory information relevant to a MOTS-C-related inquiry. An administrative inquiry is not a medication order and does not establish product availability, compounding eligibility, FDA approval, or clinical appropriateness.
Clinic Verification
Documentation Review
Phoenix Meds may help organize available documentation and current regulatory information so the clinic can identify matters requiring further review.
Licensed Parties
Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Is MOTS-C FDA approved?
FDA’s 2026 review states that MOTS-c free base and MOTS-c acetate are not components of FDA-approved drugs.
Is MOTS-C on the 503A Bulks List?
FDA evaluated MOTS-c free base and MOTS-c acetate in 2026 and proposed that neither be included on the 503A Bulks List. The advisory process is not itself a final agency determination, so current FDA information should be checked before relying on a particular status.
Are MOTS-c free base and MOTS-c acetate the same substance?
No. FDA treats them as separate bulk drug substances and pharmaceutical ingredients.
Does FDA have human clinical data for MOTS-C?
FDA states that its review did not identify clinical studies or human-exposure data for MOTS-c administered by any route
Does Phoenix Meds compound or dispense MOTS-C?
No. Phoenix does not compound, manufacture, dispense, test, ship, or take custody of MOTS-C.
What can Phoenix Meds help clinics with?
Our work is administrative and may include credential review, document organization, review of publicly available regulatory information, and professional communication.
Does Phoenix provide MOTS-C dosing or treatment protocols?
No. We do not provide dosing, treatment protocols, or clinical recommendations.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, drug manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present MOTS-C as an FDA-approved treatment and does not establish that a particular compounding or distribution pathway is available or permitted.